Johannes Levin, MD, Ludwig-Maximilians-Universität München, Munich, Germany, discusses if findings from monogenic dementias can inform sporadic Alzheimer’s disease (AD) research. Prof. Levin discusses a study whereby individuals from populations with monogenic dementias are followed from health into disease onset while monitoring biomarkers and cognitive changes. This approach allows for a better understanding of the step-by-step process of AD onset. Thus, enabling the development of novel strategies to treat these individuals. Furthermore, Prof. Levin addresses the similarity between genetic and sporadic cases: the age of disease onset is the most evident difference, while clinical disease course and depiction are very similar. With the weight of similarity in the clinical course, molecular configuration, and histopathology between genetic and sporadic AD, it is clear that monogenic dementia cases can be used to help inform sporadic AD research. This interview was conducted during the 2022 World Congress on Controversies in Neurology (CONy) meeting.
